NESIRITIDE CITRATE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20920lbl.pdf

Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide (BNP), which is normally produced by the ventricular myocardium. Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritid was sold under brand name Natrecor for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Atrial natriuretic peptide receptor 2 Target ID: CHEMBL2111337 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20920lbl.pdf	Binding Agent 1076

Conditions

Condition	Modality	Targets	Highest Phase	Product
acutely decompensated heart failure 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20920lbl.pdf	Primary		Approved 8583	NATRECOR Approved Use NATRECOR® is a natriuretic peptide indicated for the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. In this population, the use of NATRECOR® reduced pulmonary capillary wedge pressure and improved symptomatic dyspnea when measured at 3 hours of infusion Launch Date 2001

PubMed

Title	Date	PubMed
Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.	2015-12	26123415
Renal subanalysis of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF): the end of nesiritide as a cardiorenal therapeutic?	2014-09-16	25074508

Sample Use Guides

In Vivo Use Guide

The recommended dose of Natrecor (nesiritide) is an IV bolus of 2 µg/kg followed by a continuous infusion at a dose of 0.01 µg/kg/min. Natrecor should not be initiated at a dose that is above the recommended dose. Prime the IV tubing with an infusion of 25 mL prior to connecting to the patient's vascular access port and prior to administering the bolus or starting the infusion.

Route of Administration: Intravenous

Substance Class	Protein Created by `admin` on `Mon Mar 31 20:35:58 GMT 2025` Edited by `admin` on `Mon Mar 31 20:35:58 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	EL5U85UKD2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NESIRITIDE CITRATE

Official Name

English

NATRECOR

Preferred Name

English

NESIRITIDE CITRATE [MART.]

Common Name

English

Nesiritide citrate [WHO-DD]

Common Name

English

SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS (CYS 10-26 -DISULFIDE) CITRATE

Systematic Name

English

NESIRITIDE CITRATE [USAN]

Common Name

English

NATRIURETIC FACTOR-32 (HUMAN BRAIN CLONE .LAMBDA.HBNP57), 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (SALT)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29707